Canadian International Air Show Celebrates 75 years of Soaring over Toronto
February 09, 2024 09:30 ET
|
Canadian International Air Show
TORONTO, Feb. 09, 2024 (GLOBE NEWSWIRE) -- The Canadian International Air Show (CIAS) officially announces their 75th Anniversary performance headliners. The 2024 initial lineup includes the...
Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company
November 22, 2022 07:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that the Board of Directors of the Company acting solely by all of its independent and...
Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results
August 09, 2022 16:00 ET
|
Cyclerion Therapeutics, Inc.
Positive topline results for CY6463 announced in two clinical studies in patients with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Cognitive Impairment...
Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)
July 28, 2022 07:00 ET
|
Cyclerion Therapeutics, Inc.
Study data demonstrate positive effects of CY6463 on cognition and inflammation after two weeks of dosing in patients with stable schizophrenia on standard of care Oral, once-daily CY6463 was well...
Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results
May 04, 2022 16:01 ET
|
Cyclerion Therapeutics, Inc.
Characterizing the novel neuropharmacology of CY6463’s NO-sGC-cGMP signal modulation in an integrated clinical strategy currently involving three ongoing, exploratory, biomarker-rich, signal seeking...
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
February 24, 2022 16:01 ET
|
Cyclerion Therapeutics, Inc.
Phase 2a study in Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) enrollment closed; topline data expected in Q2 2022 Phase 1b study in Cognitive Impairment...
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
February 23, 2022 08:00 ET
|
Cyclerion Therapeutics, Inc.
CAMBRIDGE, Mass. and PARIS, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma today announced an artificial intelligence-driven, precision medicine...
Première apparition canadienne à Toronto pour le véhicule concept INFINITI QX Inspiration
February 14, 2019 18:04 ET
|
INFINITI
Le QX Inspiration laisse entrevoir le futur design de la gamme électrique haute performance d’INFINITI.Il est l’œuvre du Canadien Karim Habib, directeur général du design, INFINITI Motor Company, Ltd....
INFINITI QX Inspiration Concept Makes Canadian Debut in Toronto
February 14, 2019 18:04 ET
|
INFINITI
The INFINITI QX Inspiration signals the future of INFINITI design and vision for high-performance electrified vehiclesConcept led by Canadian Karim Habib, Executive Design Director, INFINITI Motor...
Charfen Institute Ranks #21 on the 2011 Inc. 500 List of America's Fastest Growing Private Companies
August 25, 2011 13:08 ET
|
Charfen Institute
Austin, Texas, Aug. 25, 2011 (GLOBE NEWSWIRE) -- Less than four years ago, Alex and Cadey Charfen were in bankruptcy court and numbered among the many casualties of the U.S. real estate market’s...